ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ...
– Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threatening – – In a global ...
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD. The Food and Drug Administration (FDA) has approved ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Actemra? Actemra contains the active ingredient ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Actemra? Actemra contains the active ingredient ...
Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease ...
GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra ...
If you have certain medical conditions, your doctor may prescribe Kineret for you. Kineret is a prescription drug that’s used to treat: rheumatoid arthritis neonatal-onset multisystem inflammatory ...
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...